CLINICAL AND BACTERIOLOGICAL EVALUATION OF TMS-19-Q IN SUPERFICIAL SUPPURATIVE SKIN AND SOFT TISSUE INFECTION
Clinical effectiveness of TMS-19-Q, a new macrolide antibiotic, was evaluated in superficial infectious diseases classified into 6 groups at 13 departments of dermatology. The results obtained were as follows: 1. Final global improvement rating in 311 cases were excellent in 91, good in 158, fair in...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of antibiotics 1985/03/25, Vol.38(3), pp.575-594 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 594 |
|---|---|
| container_issue | 3 |
| container_start_page | 575 |
| container_title | Japanese journal of antibiotics |
| container_volume | 38 |
| creator | KUKITA, ATSUSHI NONAMI, EIICHIRO TAGAMI, HACHIRO URABE, HARUKUNI NAKAGAWA, HIDEMI TAKIWAKI, HIROTSUGU TAKAHASHI, HISASHI TSUKINAGA, ICHIRO TAKEDA, KATSUYUKI FUJITA, KEIICHI TAKIZAWA, KIYOHIRO TODA, KIYOSHI YAMADA, KIYOSHI IMURA, MAKOTO HOSHINO, MANABU TASHIRO, MASAAKI NOHARA, NOZOMI SEKINE, RUMIKO ARASE, SEIJI UMEMURA, SHIGEO NOMOTO, SHIGERU WATANABE, SHINICHI SHIMADA, SHINJI MERA, SHUJI HANAWA, SINTARO SHISHIBA, TAKAKO KAGESHITA, TASHIRO YAMANO, TATSUFUMI ARAO, TATSUYOSHI ASADA, YASUO TANITA, YASUO KIMURA, YASUTAKA MIURA, YUSHO |
| description | Clinical effectiveness of TMS-19-Q, a new macrolide antibiotic, was evaluated in superficial infectious diseases classified into 6 groups at 13 departments of dermatology. The results obtained were as follows: 1. Final global improvement rating in 311 cases were excellent in 91, good in 158, fair in 45 and poor in 17 and the effective rate was 80.1%. 2. Effective rates in each group were 71.1% in 1st group (folliculitis and acne pustulosa), 78.6%. in 2nd group (furuncle, furunculosis and carbuncle), 100% in 3rd group (impetigo), 76.9% in 4th group (phlegmone, superficial lymphangitis, erysipelas and infectious paronychia), 88.7% in 5th group (inflammatory atheroma, subcutaneous abscess, hidradenitis suppurative and acne conglobata) and 77.3% in 6th group (secondary infection). 3. Dominant strains isolated were S. aureus (40.7%), S. epidermidis (26.9%) and anaerobic bacteria (20.8%). S. aureus was frequently isolated from most of all disease. On the other hand, S. epidermidis and anaerobic bacteria were isolated mainly from 1st and 5th group. 4. Optimum daily doses would be over 600mg. 5. Slight adverse reactions such as gastrointestinal disorders, eruption and malaise were observed in 12 cases. |
| doi_str_mv | 10.11553/antibiotics1968b.38.575 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_76283032</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76283032</sourcerecordid><originalsourceid>FETCH-LOGICAL-j188t-6ff27eb724afb3591bb29eda8da8c49b81eb5f9039c05dd7e128a2ab8d31dcaf3</originalsourceid><addsrcrecordid>eNpdkVFPgzAUhRujmcvcTzDpk29M2g5aHhFBUYQ5YK-khaIY2CZlD_57O0f2YNLcNvd89zQ5FwCIzAVClkXu-XZoRLMbmlIhx2ZiQdjCotYFmGLEbMNaUnoJpiaxmYEpQ9dgrlQjTIIow9phAiaEOdQ2zSnovCiMQ8-NoBs_wgfXy_x1mETJ01_P37hR7mZhEsMkgNlbaiDHeIdhDNN85a-D0As1pd-rfK2xjQ_TVy0erdIkyGAWpmnuaz7wvaPLDbiqeavkfLxnIA_8zHs2xg-NL8TYYNh1jakUFC95LYjlICGwIyvO9CmXjmBICqt2TOKUplVVVCLMOOaCVQRVJa_JDNydfPf97vsg1VB0jSpl2_Kt3B1UQW3MiEmwBm9H8CA6WRX7vul4_1OM-Wj95aR_qYF_yLPOex1-K4v_m9CDBTkWvY4zVH7yvpBb8gsdan7p</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76283032</pqid></control><display><type>article</type><title>CLINICAL AND BACTERIOLOGICAL EVALUATION OF TMS-19-Q IN SUPERFICIAL SUPPURATIVE SKIN AND SOFT TISSUE INFECTION</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>KUKITA, ATSUSHI ; NONAMI, EIICHIRO ; TAGAMI, HACHIRO ; URABE, HARUKUNI ; NAKAGAWA, HIDEMI ; TAKIWAKI, HIROTSUGU ; TAKAHASHI, HISASHI ; TSUKINAGA, ICHIRO ; TAKEDA, KATSUYUKI ; FUJITA, KEIICHI ; TAKIZAWA, KIYOHIRO ; TODA, KIYOSHI ; YAMADA, KIYOSHI ; IMURA, MAKOTO ; HOSHINO, MANABU ; TASHIRO, MASAAKI ; NOHARA, NOZOMI ; SEKINE, RUMIKO ; ARASE, SEIJI ; UMEMURA, SHIGEO ; NOMOTO, SHIGERU ; WATANABE, SHINICHI ; SHIMADA, SHINJI ; MERA, SHUJI ; HANAWA, SINTARO ; SHISHIBA, TAKAKO ; KAGESHITA, TASHIRO ; YAMANO, TATSUFUMI ; ARAO, TATSUYOSHI ; ASADA, YASUO ; TANITA, YASUO ; KIMURA, YASUTAKA ; MIURA, YUSHO</creator><creatorcontrib>KUKITA, ATSUSHI ; NONAMI, EIICHIRO ; TAGAMI, HACHIRO ; URABE, HARUKUNI ; NAKAGAWA, HIDEMI ; TAKIWAKI, HIROTSUGU ; TAKAHASHI, HISASHI ; TSUKINAGA, ICHIRO ; TAKEDA, KATSUYUKI ; FUJITA, KEIICHI ; TAKIZAWA, KIYOHIRO ; TODA, KIYOSHI ; YAMADA, KIYOSHI ; IMURA, MAKOTO ; HOSHINO, MANABU ; TASHIRO, MASAAKI ; NOHARA, NOZOMI ; SEKINE, RUMIKO ; ARASE, SEIJI ; UMEMURA, SHIGEO ; NOMOTO, SHIGERU ; WATANABE, SHINICHI ; SHIMADA, SHINJI ; MERA, SHUJI ; HANAWA, SINTARO ; SHISHIBA, TAKAKO ; KAGESHITA, TASHIRO ; YAMANO, TATSUFUMI ; ARAO, TATSUYOSHI ; ASADA, YASUO ; TANITA, YASUO ; KIMURA, YASUTAKA ; MIURA, YUSHO</creatorcontrib><description>Clinical effectiveness of TMS-19-Q, a new macrolide antibiotic, was evaluated in superficial infectious diseases classified into 6 groups at 13 departments of dermatology. The results obtained were as follows: 1. Final global improvement rating in 311 cases were excellent in 91, good in 158, fair in 45 and poor in 17 and the effective rate was 80.1%. 2. Effective rates in each group were 71.1% in 1st group (folliculitis and acne pustulosa), 78.6%. in 2nd group (furuncle, furunculosis and carbuncle), 100% in 3rd group (impetigo), 76.9% in 4th group (phlegmone, superficial lymphangitis, erysipelas and infectious paronychia), 88.7% in 5th group (inflammatory atheroma, subcutaneous abscess, hidradenitis suppurative and acne conglobata) and 77.3% in 6th group (secondary infection). 3. Dominant strains isolated were S. aureus (40.7%), S. epidermidis (26.9%) and anaerobic bacteria (20.8%). S. aureus was frequently isolated from most of all disease. On the other hand, S. epidermidis and anaerobic bacteria were isolated mainly from 1st and 5th group. 4. Optimum daily doses would be over 600mg. 5. Slight adverse reactions such as gastrointestinal disorders, eruption and malaise were observed in 12 cases.</description><identifier>ISSN: 0368-2781</identifier><identifier>EISSN: 2186-5477</identifier><identifier>DOI: 10.11553/antibiotics1968b.38.575</identifier><identifier>PMID: 3897600</identifier><language>jpn</language><publisher>Japan: Japan Antibiotics Research Association</publisher><subject>Adolescent ; Adult ; Aged ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - therapeutic use ; Child ; Clinical Trials as Topic ; Dermatitis - drug therapy ; Dermatitis - microbiology ; Drug Resistance, Microbial ; Female ; Folliculitis - drug therapy ; Furunculosis - drug therapy ; Humans ; Leucomycins - administration & dosage ; Leucomycins - therapeutic use ; Male ; Middle Aged ; Miocamycin - analogs & derivatives ; Staphylococcus aureus - isolation & purification ; Staphylococcus epidermidis - isolation & purification ; Tablets</subject><ispartof>The Japanese Journal of Antibiotics, 1985/03/25, Vol.38(3), pp.575-594</ispartof><rights>Japan Antibiotics Research Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3897600$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KUKITA, ATSUSHI</creatorcontrib><creatorcontrib>NONAMI, EIICHIRO</creatorcontrib><creatorcontrib>TAGAMI, HACHIRO</creatorcontrib><creatorcontrib>URABE, HARUKUNI</creatorcontrib><creatorcontrib>NAKAGAWA, HIDEMI</creatorcontrib><creatorcontrib>TAKIWAKI, HIROTSUGU</creatorcontrib><creatorcontrib>TAKAHASHI, HISASHI</creatorcontrib><creatorcontrib>TSUKINAGA, ICHIRO</creatorcontrib><creatorcontrib>TAKEDA, KATSUYUKI</creatorcontrib><creatorcontrib>FUJITA, KEIICHI</creatorcontrib><creatorcontrib>TAKIZAWA, KIYOHIRO</creatorcontrib><creatorcontrib>TODA, KIYOSHI</creatorcontrib><creatorcontrib>YAMADA, KIYOSHI</creatorcontrib><creatorcontrib>IMURA, MAKOTO</creatorcontrib><creatorcontrib>HOSHINO, MANABU</creatorcontrib><creatorcontrib>TASHIRO, MASAAKI</creatorcontrib><creatorcontrib>NOHARA, NOZOMI</creatorcontrib><creatorcontrib>SEKINE, RUMIKO</creatorcontrib><creatorcontrib>ARASE, SEIJI</creatorcontrib><creatorcontrib>UMEMURA, SHIGEO</creatorcontrib><creatorcontrib>NOMOTO, SHIGERU</creatorcontrib><creatorcontrib>WATANABE, SHINICHI</creatorcontrib><creatorcontrib>SHIMADA, SHINJI</creatorcontrib><creatorcontrib>MERA, SHUJI</creatorcontrib><creatorcontrib>HANAWA, SINTARO</creatorcontrib><creatorcontrib>SHISHIBA, TAKAKO</creatorcontrib><creatorcontrib>KAGESHITA, TASHIRO</creatorcontrib><creatorcontrib>YAMANO, TATSUFUMI</creatorcontrib><creatorcontrib>ARAO, TATSUYOSHI</creatorcontrib><creatorcontrib>ASADA, YASUO</creatorcontrib><creatorcontrib>TANITA, YASUO</creatorcontrib><creatorcontrib>KIMURA, YASUTAKA</creatorcontrib><creatorcontrib>MIURA, YUSHO</creatorcontrib><title>CLINICAL AND BACTERIOLOGICAL EVALUATION OF TMS-19-Q IN SUPERFICIAL SUPPURATIVE SKIN AND SOFT TISSUE INFECTION</title><title>Japanese journal of antibiotics</title><addtitle>Jpn. J. Antibiotics</addtitle><description>Clinical effectiveness of TMS-19-Q, a new macrolide antibiotic, was evaluated in superficial infectious diseases classified into 6 groups at 13 departments of dermatology. The results obtained were as follows: 1. Final global improvement rating in 311 cases were excellent in 91, good in 158, fair in 45 and poor in 17 and the effective rate was 80.1%. 2. Effective rates in each group were 71.1% in 1st group (folliculitis and acne pustulosa), 78.6%. in 2nd group (furuncle, furunculosis and carbuncle), 100% in 3rd group (impetigo), 76.9% in 4th group (phlegmone, superficial lymphangitis, erysipelas and infectious paronychia), 88.7% in 5th group (inflammatory atheroma, subcutaneous abscess, hidradenitis suppurative and acne conglobata) and 77.3% in 6th group (secondary infection). 3. Dominant strains isolated were S. aureus (40.7%), S. epidermidis (26.9%) and anaerobic bacteria (20.8%). S. aureus was frequently isolated from most of all disease. On the other hand, S. epidermidis and anaerobic bacteria were isolated mainly from 1st and 5th group. 4. Optimum daily doses would be over 600mg. 5. Slight adverse reactions such as gastrointestinal disorders, eruption and malaise were observed in 12 cases.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Child</subject><subject>Clinical Trials as Topic</subject><subject>Dermatitis - drug therapy</subject><subject>Dermatitis - microbiology</subject><subject>Drug Resistance, Microbial</subject><subject>Female</subject><subject>Folliculitis - drug therapy</subject><subject>Furunculosis - drug therapy</subject><subject>Humans</subject><subject>Leucomycins - administration & dosage</subject><subject>Leucomycins - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Miocamycin - analogs & derivatives</subject><subject>Staphylococcus aureus - isolation & purification</subject><subject>Staphylococcus epidermidis - isolation & purification</subject><subject>Tablets</subject><issn>0368-2781</issn><issn>2186-5477</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkVFPgzAUhRujmcvcTzDpk29M2g5aHhFBUYQ5YK-khaIY2CZlD_57O0f2YNLcNvd89zQ5FwCIzAVClkXu-XZoRLMbmlIhx2ZiQdjCotYFmGLEbMNaUnoJpiaxmYEpQ9dgrlQjTIIow9phAiaEOdQ2zSnovCiMQ8-NoBs_wgfXy_x1mETJ01_P37hR7mZhEsMkgNlbaiDHeIdhDNN85a-D0As1pd-rfK2xjQ_TVy0erdIkyGAWpmnuaz7wvaPLDbiqeavkfLxnIA_8zHs2xg-NL8TYYNh1jakUFC95LYjlICGwIyvO9CmXjmBICqt2TOKUplVVVCLMOOaCVQRVJa_JDNydfPf97vsg1VB0jSpl2_Kt3B1UQW3MiEmwBm9H8CA6WRX7vul4_1OM-Wj95aR_qYF_yLPOex1-K4v_m9CDBTkWvY4zVH7yvpBb8gsdan7p</recordid><startdate>198503</startdate><enddate>198503</enddate><creator>KUKITA, ATSUSHI</creator><creator>NONAMI, EIICHIRO</creator><creator>TAGAMI, HACHIRO</creator><creator>URABE, HARUKUNI</creator><creator>NAKAGAWA, HIDEMI</creator><creator>TAKIWAKI, HIROTSUGU</creator><creator>TAKAHASHI, HISASHI</creator><creator>TSUKINAGA, ICHIRO</creator><creator>TAKEDA, KATSUYUKI</creator><creator>FUJITA, KEIICHI</creator><creator>TAKIZAWA, KIYOHIRO</creator><creator>TODA, KIYOSHI</creator><creator>YAMADA, KIYOSHI</creator><creator>IMURA, MAKOTO</creator><creator>HOSHINO, MANABU</creator><creator>TASHIRO, MASAAKI</creator><creator>NOHARA, NOZOMI</creator><creator>SEKINE, RUMIKO</creator><creator>ARASE, SEIJI</creator><creator>UMEMURA, SHIGEO</creator><creator>NOMOTO, SHIGERU</creator><creator>WATANABE, SHINICHI</creator><creator>SHIMADA, SHINJI</creator><creator>MERA, SHUJI</creator><creator>HANAWA, SINTARO</creator><creator>SHISHIBA, TAKAKO</creator><creator>KAGESHITA, TASHIRO</creator><creator>YAMANO, TATSUFUMI</creator><creator>ARAO, TATSUYOSHI</creator><creator>ASADA, YASUO</creator><creator>TANITA, YASUO</creator><creator>KIMURA, YASUTAKA</creator><creator>MIURA, YUSHO</creator><general>Japan Antibiotics Research Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>198503</creationdate><title>CLINICAL AND BACTERIOLOGICAL EVALUATION OF TMS-19-Q IN SUPERFICIAL SUPPURATIVE SKIN AND SOFT TISSUE INFECTION</title><author>KUKITA, ATSUSHI ; NONAMI, EIICHIRO ; TAGAMI, HACHIRO ; URABE, HARUKUNI ; NAKAGAWA, HIDEMI ; TAKIWAKI, HIROTSUGU ; TAKAHASHI, HISASHI ; TSUKINAGA, ICHIRO ; TAKEDA, KATSUYUKI ; FUJITA, KEIICHI ; TAKIZAWA, KIYOHIRO ; TODA, KIYOSHI ; YAMADA, KIYOSHI ; IMURA, MAKOTO ; HOSHINO, MANABU ; TASHIRO, MASAAKI ; NOHARA, NOZOMI ; SEKINE, RUMIKO ; ARASE, SEIJI ; UMEMURA, SHIGEO ; NOMOTO, SHIGERU ; WATANABE, SHINICHI ; SHIMADA, SHINJI ; MERA, SHUJI ; HANAWA, SINTARO ; SHISHIBA, TAKAKO ; KAGESHITA, TASHIRO ; YAMANO, TATSUFUMI ; ARAO, TATSUYOSHI ; ASADA, YASUO ; TANITA, YASUO ; KIMURA, YASUTAKA ; MIURA, YUSHO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j188t-6ff27eb724afb3591bb29eda8da8c49b81eb5f9039c05dd7e128a2ab8d31dcaf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>1985</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Child</topic><topic>Clinical Trials as Topic</topic><topic>Dermatitis - drug therapy</topic><topic>Dermatitis - microbiology</topic><topic>Drug Resistance, Microbial</topic><topic>Female</topic><topic>Folliculitis - drug therapy</topic><topic>Furunculosis - drug therapy</topic><topic>Humans</topic><topic>Leucomycins - administration & dosage</topic><topic>Leucomycins - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Miocamycin - analogs & derivatives</topic><topic>Staphylococcus aureus - isolation & purification</topic><topic>Staphylococcus epidermidis - isolation & purification</topic><topic>Tablets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KUKITA, ATSUSHI</creatorcontrib><creatorcontrib>NONAMI, EIICHIRO</creatorcontrib><creatorcontrib>TAGAMI, HACHIRO</creatorcontrib><creatorcontrib>URABE, HARUKUNI</creatorcontrib><creatorcontrib>NAKAGAWA, HIDEMI</creatorcontrib><creatorcontrib>TAKIWAKI, HIROTSUGU</creatorcontrib><creatorcontrib>TAKAHASHI, HISASHI</creatorcontrib><creatorcontrib>TSUKINAGA, ICHIRO</creatorcontrib><creatorcontrib>TAKEDA, KATSUYUKI</creatorcontrib><creatorcontrib>FUJITA, KEIICHI</creatorcontrib><creatorcontrib>TAKIZAWA, KIYOHIRO</creatorcontrib><creatorcontrib>TODA, KIYOSHI</creatorcontrib><creatorcontrib>YAMADA, KIYOSHI</creatorcontrib><creatorcontrib>IMURA, MAKOTO</creatorcontrib><creatorcontrib>HOSHINO, MANABU</creatorcontrib><creatorcontrib>TASHIRO, MASAAKI</creatorcontrib><creatorcontrib>NOHARA, NOZOMI</creatorcontrib><creatorcontrib>SEKINE, RUMIKO</creatorcontrib><creatorcontrib>ARASE, SEIJI</creatorcontrib><creatorcontrib>UMEMURA, SHIGEO</creatorcontrib><creatorcontrib>NOMOTO, SHIGERU</creatorcontrib><creatorcontrib>WATANABE, SHINICHI</creatorcontrib><creatorcontrib>SHIMADA, SHINJI</creatorcontrib><creatorcontrib>MERA, SHUJI</creatorcontrib><creatorcontrib>HANAWA, SINTARO</creatorcontrib><creatorcontrib>SHISHIBA, TAKAKO</creatorcontrib><creatorcontrib>KAGESHITA, TASHIRO</creatorcontrib><creatorcontrib>YAMANO, TATSUFUMI</creatorcontrib><creatorcontrib>ARAO, TATSUYOSHI</creatorcontrib><creatorcontrib>ASADA, YASUO</creatorcontrib><creatorcontrib>TANITA, YASUO</creatorcontrib><creatorcontrib>KIMURA, YASUTAKA</creatorcontrib><creatorcontrib>MIURA, YUSHO</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of antibiotics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KUKITA, ATSUSHI</au><au>NONAMI, EIICHIRO</au><au>TAGAMI, HACHIRO</au><au>URABE, HARUKUNI</au><au>NAKAGAWA, HIDEMI</au><au>TAKIWAKI, HIROTSUGU</au><au>TAKAHASHI, HISASHI</au><au>TSUKINAGA, ICHIRO</au><au>TAKEDA, KATSUYUKI</au><au>FUJITA, KEIICHI</au><au>TAKIZAWA, KIYOHIRO</au><au>TODA, KIYOSHI</au><au>YAMADA, KIYOSHI</au><au>IMURA, MAKOTO</au><au>HOSHINO, MANABU</au><au>TASHIRO, MASAAKI</au><au>NOHARA, NOZOMI</au><au>SEKINE, RUMIKO</au><au>ARASE, SEIJI</au><au>UMEMURA, SHIGEO</au><au>NOMOTO, SHIGERU</au><au>WATANABE, SHINICHI</au><au>SHIMADA, SHINJI</au><au>MERA, SHUJI</au><au>HANAWA, SINTARO</au><au>SHISHIBA, TAKAKO</au><au>KAGESHITA, TASHIRO</au><au>YAMANO, TATSUFUMI</au><au>ARAO, TATSUYOSHI</au><au>ASADA, YASUO</au><au>TANITA, YASUO</au><au>KIMURA, YASUTAKA</au><au>MIURA, YUSHO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CLINICAL AND BACTERIOLOGICAL EVALUATION OF TMS-19-Q IN SUPERFICIAL SUPPURATIVE SKIN AND SOFT TISSUE INFECTION</atitle><jtitle>Japanese journal of antibiotics</jtitle><addtitle>Jpn. J. Antibiotics</addtitle><date>1985-03</date><risdate>1985</risdate><volume>38</volume><issue>3</issue><spage>575</spage><epage>594</epage><pages>575-594</pages><issn>0368-2781</issn><eissn>2186-5477</eissn><abstract>Clinical effectiveness of TMS-19-Q, a new macrolide antibiotic, was evaluated in superficial infectious diseases classified into 6 groups at 13 departments of dermatology. The results obtained were as follows: 1. Final global improvement rating in 311 cases were excellent in 91, good in 158, fair in 45 and poor in 17 and the effective rate was 80.1%. 2. Effective rates in each group were 71.1% in 1st group (folliculitis and acne pustulosa), 78.6%. in 2nd group (furuncle, furunculosis and carbuncle), 100% in 3rd group (impetigo), 76.9% in 4th group (phlegmone, superficial lymphangitis, erysipelas and infectious paronychia), 88.7% in 5th group (inflammatory atheroma, subcutaneous abscess, hidradenitis suppurative and acne conglobata) and 77.3% in 6th group (secondary infection). 3. Dominant strains isolated were S. aureus (40.7%), S. epidermidis (26.9%) and anaerobic bacteria (20.8%). S. aureus was frequently isolated from most of all disease. On the other hand, S. epidermidis and anaerobic bacteria were isolated mainly from 1st and 5th group. 4. Optimum daily doses would be over 600mg. 5. Slight adverse reactions such as gastrointestinal disorders, eruption and malaise were observed in 12 cases.</abstract><cop>Japan</cop><pub>Japan Antibiotics Research Association</pub><pmid>3897600</pmid><doi>10.11553/antibiotics1968b.38.575</doi><tpages>20</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0368-2781 |
| ispartof | The Japanese Journal of Antibiotics, 1985/03/25, Vol.38(3), pp.575-594 |
| issn | 0368-2781 2186-5477 |
| language | jpn |
| recordid | cdi_proquest_miscellaneous_76283032 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Adult Aged Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use Child Clinical Trials as Topic Dermatitis - drug therapy Dermatitis - microbiology Drug Resistance, Microbial Female Folliculitis - drug therapy Furunculosis - drug therapy Humans Leucomycins - administration & dosage Leucomycins - therapeutic use Male Middle Aged Miocamycin - analogs & derivatives Staphylococcus aureus - isolation & purification Staphylococcus epidermidis - isolation & purification Tablets |
| title | CLINICAL AND BACTERIOLOGICAL EVALUATION OF TMS-19-Q IN SUPERFICIAL SUPPURATIVE SKIN AND SOFT TISSUE INFECTION |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A19%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CLINICAL%20AND%20BACTERIOLOGICAL%20EVALUATION%20OF%20TMS-19-Q%20IN%20SUPERFICIAL%20SUPPURATIVE%20SKIN%20AND%20SOFT%20TISSUE%20INFECTION&rft.jtitle=Japanese%20journal%20of%20antibiotics&rft.au=KUKITA,%20ATSUSHI&rft.date=1985-03&rft.volume=38&rft.issue=3&rft.spage=575&rft.epage=594&rft.pages=575-594&rft.issn=0368-2781&rft.eissn=2186-5477&rft_id=info:doi/10.11553/antibiotics1968b.38.575&rft_dat=%3Cproquest_pubme%3E76283032%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76283032&rft_id=info:pmid/3897600&rfr_iscdi=true |